tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Moutabarrik A et al. In vitro FK506 kidney tubular cell toxicity. 1992 Transpl. Int. pmid:14621743
Moutabarrik A et al. FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells. 1992 Transpl. Int. pmid:14621744
Stangl MJ et al. The use of FK506 and RS61443 for reversal of small-bowel rejection. 1992 Transpl. Int. pmid:14621800
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Wijnen RM et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. 1992 Transpl. Int. pmid:14621844
Lee C et al. FK-506 binding protein from Tolypocladium inflatum: resistance of FKBP/FK-506 complex against proteolysis. 1992 Biochem. Biophys. Res. Commun. pmid:1371677
Jiang H et al. Control of humoral and cellular immunity-mediated accelerated heart allograft rejection in sensitized rats by low dose FK 506 and splenectomy. 1992 Transpl. Int. pmid:14621859
Edkins RD et al. Comparison of cyclosporine and FK506 effects on glutathione levels in rat cochlea, brain, liver and kidney. 1992 Biochem. Pharmacol. pmid:1371687
Kobayashi N et al. Abdominal organ cluster transplantation in pigs and FK506. 1992 Transpl. Int. pmid:14621861
Galat A et al. A rapamycin-selective 25-kDa immunophilin. 1992 Biochemistry pmid:1371698
Hanawa H et al. An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. 1992 Clin. Immunol. Immunopathol. pmid:1371730
Hiraoka Y et al. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. 1992 J. Pharmacol. Exp. Ther. pmid:1372051
Chen TS et al. Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 J. Antibiot. pmid:1372307
Morisaki M and Arai T Identity of immunosuppressant FR-900520 with ascomycin. 1992 J. Antibiot. pmid:1372308
Sakr M et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. 1992 Transplantation pmid:1374948
Lepre CA et al. Solution structure of FK506 bound to FKBP-12. 1992 FEBS Lett. pmid:1375171
Ruff VA et al. FKBP-12 is not an inhibitor of protein kinase C. 1992 Immunol. Invest. pmid:1375189
Kawaguchi S [Effects of FK506 on aminonucleoside-induced nephrotic rats]. 1992 Nihon Jinzo Gakkai Shi pmid:1375300
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Chen TS et al. Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by an unidentified Actinomycete ATCC 53828 [corrected]. 1992 J. Antibiot. pmid:1375593
Yagihashi A et al. Changes in cell surface markers in human small bowel transplantation with FK 506. 1992 Transplant. Proc. pmid:1376522
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. 1992 Transplant. Proc. pmid:1376532
Demetris AJ et al. Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. 1992 Lancet pmid:1376851
Ichihashi T et al. Haemolytic uraemic syndrome during FK506 therapy. 1992 Lancet pmid:1376852
O'Keefe SJ et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. 1992 Nature pmid:1377361
Souza ER et al. Acute effects of FK 506 on glomerular hemodynamics. 1992 Transplant. Proc. pmid:1281585
Hanke JH et al. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. 1992 Lymphokine Cytokine Res. pmid:1281674
Logan TM et al. Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments. 1992 FEBS Lett. pmid:1281793
Bergstrand H et al. Modulation of neutrophil superoxide generation by inhibitors of protein kinase C, calmodulin, diacylglycerol and myosin light chain kinases, and peptidyl prolyl cis-trans isomerase. 1992 J. Pharmacol. Exp. Ther. pmid:1281879
DiLella AG et al. Chromosomal band assignments of the genes encoding human FKBP12 and FKBP13. 1992 Biochem. Biophys. Res. Commun. pmid:1281998
Sawada M et al. Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide. 1992 Biochem. Biophys. Res. Commun. pmid:1282000
Minoda M et al. Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. 1992 Microbiol. Immunol. pmid:1282197
Langrehr JM et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. 1992 J. Clin. Invest. pmid:1379617
Kumano K et al. [Functional and morphological changes in rat kidney induced by FK506 and its reversal by various vasodilators]. 1992 Nippon Hinyokika Gakkai Zasshi pmid:1379657
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Kobayashi N et al. Abdominal organ cluster transplantation in pigs receiving FK 506. 1992 Transplant. Proc. pmid:1379754
Yoshimura R et al. A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. 1992 Transplant. Proc. pmid:1379755
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Friccius H et al. The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells. 1992 Int. J. Immunopharmacol. pmid:1380951
Dumont FJ et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. 1992 J. Exp. Med. pmid:1380976
Norris AA et al. Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs. 1992 Clin. Exp. Immunol. pmid:1381297
Karpas A et al. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1381509
Yatscoff RW and Shaw LM Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. 1992 Ther Drug Monit pmid:1381530
Arceci RJ et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. 1992 Blood pmid:1381629
Pahl A and Keller U FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. 1992 J. Bacteriol. pmid:1381710
Siekierka JJ and Sigal NH FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. 1992 Curr. Opin. Immunol. pmid:1384551
Hultsch T et al. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. 1992 Mol. Biol. Cell pmid:1384815
Petros AM et al. Identification of solvent-exposed regions of an FK-506 analog, ascomycin, bound to FKBP using a paramagnetic probe. 1992 J. Biomol. NMR pmid:1384850
Liu J et al. The effects of FK-506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6. 1992 Int. Arch. Allergy Immunol. pmid:1384862
Mochizuki M et al. Preclinical and clinical study of FK506 in uveitis. 1992 Curr. Eye Res. pmid:1385045
Chung J et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. 1992 Cell pmid:1377606
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Arai S et al. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. 1992 Jul-Aug J. Heart Lung Transplant. pmid:1379829
Fagiuoli S et al. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. 1992 Jul-Aug Ital J Gastroenterol pmid:1381245
Tong J et al. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. 1992 Jul-Aug Haematologica pmid:1385279
Nazer H et al. FK 506 associated disorders in liver transplantation. 1992 May-Jun J. Gastroenterol. Hepatol. pmid:1377038
Bowman H and Lennard TW Immunosuppressive drugs. 1992 Nov 4-17 Br J Hosp Med pmid:1282440
Sattler M et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. 1992 Sep-Oct Drug Metab. Dispos. pmid:1385058
Watanabe K et al. Fate of long-surviving allografts in tolerant recipients induced by fractionated lymphoid irradiation, donor bone marrow cell infusion, and FK 506 after retransplantation in dogs. 1993 Transplant. Proc. pmid:7679813
Valdivia LA et al. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. 1993 Transplant. Proc. pmid:7679816
Murase N et al. Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. 1993 Transplant. Proc. pmid:7679817
Schreier MH et al. Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? 1993 Transplant. Proc. pmid:7679818
Fung J et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. 1993 Transplant. Proc. pmid:7680146
Shibata T et al. Does FK 506 accelerate the development of coronary artery disease in the transplanted heart as well as the native heart? 1993 Transplant. Proc. pmid:7680147
Todo S et al. Intestinal transplantation in humans under FK 506. 1993 Transplant. Proc. pmid:7680148
Takahara S et al. [Blood level monitoring of FK506 on kidney transplant recipients]. 1993 Nippon Hinyokika Gakkai Zasshi pmid:7504758
Lieberman I et al. Synergy between tetrandrine and FK506 in prevention of diabetes in BB rats. 1993 Life Sci. pmid:7504774
Müller MK et al. [Pathophysiologic concepts and protective possibilities in experimental pancreatic lesions]. 1993 Z Gastroenterol pmid:7504856
Bruserud O and Pawelec G Cyclosporine A and FK506 show similar immunosuppressive effects on long-term in vitro T-cell proliferation. 1993 Int. J. Immunopharmacol. pmid:7682202
Winkler M et al. Anaemia associated with FK 506 immunosuppression. 1993 Lancet pmid:7682273
Lundemose AG et al. Chlamydia trachomatis Mip-like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection. 1993 Mol. Microbiol. pmid:7682281
Akita K and Mandel TE Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. 1993 Transplant. Proc. pmid:7692650
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
David M et al. [Changes in cervix cytology in women with liver transplants treated with immunosuppressive therapy]. 1993 Zentralbl Gynakol pmid:7692689
Yatscoff RW et al. Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro. 1993 Clin. Biochem. pmid:7507804
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Ochiai T et al. Combination of immunosuppressive drugs for organ transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7509136
Wiederrecht G et al. The mechanism of action of FK-506 and cyclosporin A. 1993 Ann. N. Y. Acad. Sci. pmid:7509138
Morikawa K et al. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. 1993 Antimicrob. Agents Chemother. pmid:7509146
Jachez B et al. Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. 1993 Anticancer Drugs pmid:7683935
Shapiro R et al. FK 506 interaction with danazol. 1993 Lancet pmid:7684106
Becker JW et al. FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. 1993 J. Biol. Chem. pmid:7684380
Thomson AW et al. Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. 1993 Transpl. Immunol. pmid:7521738
Matsuura T et al. Organ-specific unresponsiveness induced by intrathymic injection of donor bone marrow cells and a short course of immunosuppression in the rat heart transplantation model. 1993 Transpl. Immunol. pmid:7521742
Fujisawa T et al. Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation. 1993 Surg. Today pmid:7686416
Ueno M et al. [Immunosuppressive effect in combination therapy of cyclosporine A, FK506 and 15-deoxyspergualin on a pancreatic islet xenotransplantation]. 1993 Nihon Geka Gakkai Zasshi pmid:7686615
Thomson AW et al. FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. 1993 Springer Semin. Immunopathol. pmid:7686690
Valdivia LA et al. Dendritic cell replacement in long-surviving liver and cardiac xenografts. 1993 Transplantation pmid:7689265
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Odocha O et al. Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689269
Hom JT and Estridge T FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils. 1993 Clin. Immunol. Immunopathol. pmid:7690315
Olivera DL et al. Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation. 1993 Clin. Immunol. Immunopathol. pmid:7690317
Whitington PF et al. Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. 1993 Lancet pmid:7690444
Zuany-Amorim C et al. Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. 1993 Br. J. Pharmacol. pmid:7694762
Hirasé Y et al. Transplantation of long-term cryopreserved allocutaneous tissue by skin graft or microsurgical anastomosis: experimental studies in the rat. 1993 Plast. Reconstr. Surg. pmid:7679796